Literature DB >> 6732426

The tyramine challenge test as a marker for melancholia.

W M Harrison, T B Cooper, J W Stewart, F M Quitkin, P J McGrath, M R Liebowitz, J R Rabkin, J S Markowitz, D F Klein.   

Abstract

A previous study reported that unipolar depressives excrete significantly lower amounts of urinary tyramine-O-sulfate following oral administration of a tyramine hydrochloride load than do normal control subjects. This study replicates and extends those findings by showing that within the heterogeneous group of unipolar depressives, patients with melancholia and bipolar patients with a history of melancholia manifest a tyramine excretion deficit. A small subgroup of medication-free patients in remission from episodes of melancholia had abnormally low tyramine sulfate excretion levels while they were euthymic, supporting the suggestion that reduced tyramine sulfate excretion following oral tyramine loading is a trait marker for depression. Further study of the role of trace amines in affective illness is warranted. Clinical application is not warranted until further evaluation of the sensitivity, specificity, and reproducibility of this oral tyramine challenge test.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6732426     DOI: 10.1001/archpsyc.1984.01790180051006

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  3 in total

1.  Atypical depressive syndromes in varying definitions.

Authors:  Jules Angst; Alex Gamma; Franco Benazzi; Brett Silverstein; Vladeta Ajdacic-Gross; Dominique Eich; Wulf Rössler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-07-27       Impact factor: 5.270

2.  High incidence of endogenous depression in migraine: confirmation by tyramine test.

Authors:  J Jarman; M Fernandez; P T Davies; V Glover; T J Steiner; C Thompson; F C Rose; M Sandler
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-07       Impact factor: 10.154

Review 3.  The epidemiology of mood disorders.

Authors:  Kathleen Ries Merikangas; Nancy C P Low
Journal:  Curr Psychiatry Rep       Date:  2004-12       Impact factor: 5.285

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.